Sunday, March 19, 2017

Mobic

Mobic





Mobic

Mobic





Mobic®
1 tablet contains 7.5 mg or 15 mg 4-hydroxy-2-methyl-N-(5-methy1-2-thiazoly0-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide meloxicam) excipients: Tablets: Sodium citrate, lactose monohydrate, microcrystalline cellulose, povidone, anhydrous colloidal silica, crospovidone, magnesium stearate. Pharmacological Properties:  Pharmacodynamic properties: Pharmacotherapeutic Group: Non Steroidal Anti-Inflammatory Agent, Oxicams ATC code: MO1AC06 Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam family, with anti-inflammatory, analgesic and antipyretic properties. The anti-inflammatory activity of meloxicam has been proven in classical models of inflammation. As with other NSAIDs, its precise mechanism of action remains unknown. However, there is at least one common mode of action shared by all NSAIDs (including Meloxicam): inhibition of the biosynthesis of prostaglandins, known inflammation mediators. Pharmacokinetic Properties: Absorption:  Meloxicam is well absorbed from the gastrointestinal tract, which is reflected by a high absolute bioavailability of 89% following oral administration (capsule).Tablets, oral suspension and capsules were shown to be bioequivalent. Following single dose administration of meloxicam, mean maximum plasma concentrations are achieved within 2 hours for the suspension and within 5-6 hours with solid oral dosage forms (capsules and tablets). With multiple dosing, steady state conditions were reached within -3 to 5 days. Once daily dosing leads to drug plasma concentrations with a relatively small peak-trough fluctuation in the range of 0.4-1.0 pg/mL for 7.5 mg doses and 0.8-2.0 pg/mL for 15 mg doses, respectively (Cm, and at steady state, respectively). Maximum plasma concentrations of meloxicam at steady state are achieved within five to six hours for the tablet, capsule and the oral suspension, respectively. Extent of absorption for meloxicam following oral administration is not altered by concomitant food intake. Distribution:  Meloxicam is very strongly bound to plasma proteins, essentially albumin (99%). Meloxicam penetrates into synovial fluid to give concentrations approximately half of those in plasma. Volume of distribution is low, on average 11 L Interindividual variation is the order of 30-40%. Biotransformation:  Meloxicam undergoes extensive hepatic biotransformation. Four different metabolites of meloxicam were identified in urine, which are all pharmacodynamically inactive. The major metabolite, 5'-carboxymeloxicam (60% of dose), is formed by oxidation of an intermediate metabolite 5'-hydroxymethylmeloxicam, which is also excreted to a lesser extent (9% of dose). In vitro studies suggest that CYP 2C9 plays an important role in this metabolic pathway, with a minor contribution from the CYP 3A4 isoenzyme.The patient's peroxidase activity is probably responsible for the other two metabolites, which account for 16% and 4% of the administered dose respectively. Elimination:  Meloxicam is excreted predominantly in the form of metabolites and occurs to equal extents in urine and faeces. Less than 5% of the daily dose is excreted unchanged in faeces, while only traces of the parent compound are excreted in urine. The mean elimination half-life is about 20 hours.Total plasma clearance amounts on average 8 mUmin.
Linearity/non-linearity; Meloxicam demonstrates linear pharmacokinetics in the therapeutic dose range of 7.5 mg 15 mg following per oral or intramuscular administration. Special populations  Hepaticirenal Insufficiency: Neither hepatic, nor mild to moderate renal insufficiencies have a substantial effect on meloxicam pharmacokinetics. In terminal renal failure, the increase in the volume of distribution may result in higher free meloxicam concentrations, and a daily dose of 7.5 mg must not be exceeded (see section Dosage and Administration). 0006- • Mean plasma clearance at steady state in elderly subjects was slightly lower than that reported for younger subjects.
Indications: - Short-term symptomatic treatment of exacerbations of osteoarthrosis. - Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis.
Contraindications: This medicinal product is contra-indicated in the following situations: - Third trimester of pregnancy (see section Pregnancy and Lactation); - Children and adolescents aged under 16 years; - Hypersensitivity to meloxicam or to one of the excipients or hypersensitivity to substances with a similar action, e.g. NSAID5, aspirin. Meloxicam should not be given to patients who have developed signs of asthma, nasal polyps, angioneurotic edema or urticaria following the administration of aspirin or other NSAID5; - History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy;
VIIIBoehringer Ingelheim
- Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); - Severely impaired liver function; - Non-dialysed severe renal failure; - Gastrointestinal bleeding, history of cerebrovascular bleeding or other bleeding disorders; - Severe heart failure.
Special Warnings and Precautions:  Undesirable effects may be minimised by-using the lowest effective dosefor the shortest duration necessary to control symptoms (see section Dosage and Administration, and GI and cardiovascular risks below). The recommended maximum daily dose should not be exceeded in case of insufficient therapeutic effect, nor should an additional NSAID be added to the therapy because this may increase the toxicity while therapeutic advantage has not been proven. The use of meloxicam with concomitant NSAID5 including cyclooxygenase-2 selective inhibitors should be avoided. Meloxicam is not appropriate for the treatment of patients requiring relief from acute pain. In the absence of improvement after several days, the clinical benefit of the treatment should be reassessed. Any history of oesophagitis, gastritis and/or peptic ulcer must be sought in order to ensure their total cure before starting treatment with meloxicam. Attention should routinely be paid to the possible onset of a recurrence in patients treated with meloxicam and with a past history of this type. Gastrointestinal effects GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section Contraindications), and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and Drug Interactions). Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment. Caution is advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as heparin as curative treatment or given in geriatrics, anticoagulants such as warfarin, or other non steroidal anti-inflammatory drugs, including acetylsalicylic acid given at anti-inflammatory doses (z lg as single intake or z 3 g as total daily amount) (see section Drug Interactions). When GI bleeding or ulceration occurs in patients receiving meloxicam, the treatment should be withdrawn. NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section Side Effects). Cardiovascular and cerebrovascular effects Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy. Clinical monitoring of blood pressure for patients at risk is recommended at baseline and especially during treatment initiation with meloxicam. Clinical trial and epidemiological data suggest that use of some NSAIDs including meloxicam (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for meloxicam. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with meloxicam after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). Skin reactions Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAID5 (see Side Effects). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Meloxicam should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Parameters of liver and renal function: As with most NSAIDs, occasional increases in serum transaminase levels, increases in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen as well as other laboratory disturbances, have been reported. The majority of these instances involved transitory and slight abnormalities. Should any such abnormality prove significant or persistent, the administration of Meloxicam should be stopped and appropriate investigations undertaken. Functional renal failure NSAIDs, by inhibiting the vasodilating effect of renal prostaglandins, may induce a functional renal failure by reduction of glomerular filtration. This adverse event is dose-dependant. At the beginning of the treatment, or after dose increase, careful monitoring of diuresis and renal function is recommended in patients with the following risk factors:
• Elderly • Concomitant treatments such as ACE inhibitors, angiotensin-II antagonists, sartans, diuretics (see section Drug Interactions) • Hypovolemia (whatever the cause) • Congestive heart failure • Renal failure • Nephrotic syndrome • Lupus nephropathy • Severe hepatic dysfunction (serum albumin < 25 g/I or Child-Pugh score a 10) In rare instance NSAIDs may be the cause of interstitial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome. The dose of meloxicam in patients with end-stage renal failure on haemodialysis should not be higher than 7.5 mg. No dose reduction is required in patients with mild or moderate renal impairment (i.e. in patients with a creatinine clearance of greater than 25 ml/min). Sodium, potassium and water retention Induction of sodium, potassium and water retention and interference with the natriuretic effects of diuretics may occur with NSAIDs. Furthermore, a decrease of the antihypertensive effect of antihypertensive drugs can occur (see section Drug Interactions). Consequently, oedema, cardiac failure or hypertension may be precipitated or exacerbated in susceptible patients as a result. Clinical monitoring is therefore necessary for patients at risk (see sections Dosage and administration and Contraindications). 6rpgdolamig Hyperkalaemia can be favoured by diabetes or concomitant treatment known to increase kalaemia (see section Drug Interactions). Regular monitoring of potassium values should be performed in such cases. Other warnings and precautions Adverse reactions are often less well tolerated in elderly, fragile or weakened individuals, who therefore require careful monitoring. As with other NSAIDs, particular caution is required in the elderly, in whom renal, hepatic and cardiac functions are frequently impaired. The elderly have an increased frequency of adverse reactions to NSAIDs especially gastro-intestinal bleeding and perforation which may be fatal (see section Dosage and Adminstration). Meloxicam, as any other NSAID may mask symptoms of an underlying infectious disease. The use of meloxicam, as with any to inhibit cyclooxygghase orostalandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of meloxicam should be considered. MOBIC 7.5 mg and 15 mg tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Effects on the ability to drive and use machines:  There are no specific studies of the ability to drive and use machinery However, on the basis of the pharmacodynamic profile and reported adverse drug reactions, meloxicam is likely to have no or negligible influence on these abilities. However, when visual disturbances or drowsiness, vertigo or other central nervous system disturbances occur, it is advisable to refrain from driving and operating machinery. Drug Interactions:  Interaction studies have only been performed in adults. Pharmacodynamic Interactions:  Other non steroidal anti-inflammatory drugs (NSAIDs)and acetylsalicylic acids 3 g/d: combination (see section Special Warnings and Precautions) with other non steroidal anti-inflammatory drugs, including acetylsalicylic acid given at anti-inflammatory doses (a 1 g as single intake or a 3 g as total daily amount) is not recommended. Corticosteroids (e.g. Glucocorticoids): The concomitant use with corticosteroids requests caution because of an increased risk of bleeding or gastrointestinal ulceration. Anticoagulant or heparin administered in geriatrics or at curative doses: Considerably increased risk of bleeding, via inhibition of platelet function and damage to the gastroduodenal mucosa. NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section Special Warnings and Precautions).The concomitant use of NSAIDs and anticoagulants or heparin administered in geriatrics or at curative dose is not recommended (see section Special Warnings and Precautions). In remaining cases of heparin use caution is necessary due to an increased bleeding risk. Careful monitoring of the INR is required if it proves impossible to avoid such combination. Thrombolytics and antiplatelet drugs: Increased risk of bleeding, via inhibition of platelet function and damage to the gastroduodenal mucosa.
Selective serotonin reuptake inhibitors (SSRls): Increased risk of gastrointestinal bleeding. Diuretics, ACE inhibitors and Angiotensin-II Antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with com-promised renal function) the co-administratin of an ACE inhibitor or Angiotensin-II antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter (see also section Special Warnings and Precautions). Other antihypertensive drugs (e.g. Beta-blockers): As for the latter, a decrease of the antihypertensive effect of beta-blockers (due to inhibition of prostaglandins with vasodilatory effect) can occur. Cakineurin inhibitors (e.g. cyclosporin, tacrolimus): Nephrotoxicity of calcineurin inhibitors may be enhanced by NSAIDs via renal prostaglandin mediated effects. During combined treatment renal function is to be measured.
A careful monitoring of the renal function is recommended, especially in the elderly. Intrauterine devices: NSAIDs have been reported to decrease the efficacy of intrauterine devices. A decrease of the efficacy of intrauterine devices by NSAIDs has been previously reported but needs further confirmation.
Pharmacokinetic Interactions: Effect of meloxicam on the oharmacokinetics of other drugs Lithium: NSAIDs have been reported to increase blood lithium levels (via decreased renal excretion of lithium), which may reach toxic values.The concomitant use of lithium and NSAIDs is not recommended (see section Special Warnings and Precautions). If this combination appears necessary, lithium plasma concentrations should be monitored carefully during the initiation, adjustment and withdrawal of meloxicam treatment.
Methotrexate: NSAIDs can reduce the tubular secretion of methotrexate thereby increasing the plasma concentrations of methotrexate. For this reason, for patients on high dosages of methotrexate (more than 15 mg/week) the concomitant use of NSAIDs is not recommended (see section Special Warnings and Precautions). The risk of an interaction between NSAID preparations and methotrexate, should be considered also in patients on low dosage of methotrexate, especially in patients with impaired renal function. In case combination treatment is necessary blood cell count and the renal function should be monitored. Caution should be taken in case both NSAID and methotrexate are given within 3 days, in which case the plasma level of methotrexate may increase and cause increased toxicity. Although the pharmacokinetics of methotrexate (15mg/week) were not relevantly affected by concomitant meloxicam treatment, it should be considered that the haematological toxicity of methotrexate can be amplified by treatment with NSAID drugs (see above). (See section Side Effects)
Pharmacokinetic Interactions: Effect of other drugs on the pharmacokinetics of meloxicam  Cholestyramine: Cholestyramine accelerates the elimination of meloxicam by interrupting the enterohepatic circulation so that clearance for meloxicam increases by 50% and the half-life decreases to 13 ± 3 hrs.This interaction is of clinical significance. No clinically relevant pharmacokinetic drug-drug interactions were detected with respect to the concomitant administration of antacids, cimetidine and digoxin.
Pregnancy and Lactation Pregnancy: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%.The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, meloxicam should not be given unless clearly necessary. If meloxicam is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to: • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension). • renal dysfunction, which may progress to renal failure with oligo-hydroamniosis. the mother and the neonate, at the end of pregnancy, to: • possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses. • inhibition of uterine contractions resulting in delayed or prolonged labour. Consequently, meloxicam is contraindicated during the third trimester of pregnancy.
While no specific experience exists for meloxicam, NSAIDs are known to pass into mother's milk. Administration therefore is not recommended in women who are breastfeeding.
Side Effects  a) General Description: Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or shekel — (see section Special Warnings and Precautions). Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment. The most commonly-observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see section Special Warnings and Precautions). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section Special Warnings and Precautions) have been reported following administration. Less frequently, gastritis has been observed. The frequencies of adverse drug reactions given below are based on corresponding occurrences of reported adverse events in 27 clinical trials with a treatment duration of at least 14 days. The information is based on clinical trials involving 15197 patients who have been treated with daily oral doses of 7.5 or 15 mg meloxicam tablets or capsules over a period of up to one year. Adverse drug reactions that have come to light as a result of reports received in relation to administration of the marketed product are included.
Adverse reactions have been ranked under headings of frequency using the following convention: Very common (a 1/10); common (a 1/100 to < 1/10); uncommon (a 1/1,000 to < 1/100); rare (51/10,000 to < 1/1.000); very rare (< 1/10,000), not known (cannot be estimated from the available data)
6) Table of adverse reactions:
System Organ Class / MedDRA PreferedTerm Frequency Blood and lymphatic system disorders Anaemia Uncommon Blood count abnormal (including differential white cell count), leukopenia, thrombocytopenia. Rare Very rare Cases of agranulocytosis have been reported (see section Information Characterising Individual Serious and/or Frequently Occurring Adverse Reactions ) Immune system disorders Allergic reactions other than anaphylactic or anaphylactoid reactions Uncommon Anaphylactic reaction, anaphylactoid reaction Not known Psychiatric disorders Mood altered, nightmares Rare Confusional state, disorientation Not known Nervous system disorders Headache Common Dizziness, somnolence Uncommon Eye disorders Visual disturbance including vision blurred; conjunctivitis Rare Eir and labyrinth disorders Vertigo Uncommon Tinnitus Rare Cardiac disorders Palpitations Rare Cardiac failure has been reported in association with NSAID treatment. Vascular disorders Blood pressure increased • (see section Special Warnings and Precautions), flushing Uncommon Respiratory, thoracic and mediastinal disorders Asthma in individuals allergic to aspirin or other NSAIDs Rare Gastrointestinal disorders Dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhoea Very common Occult or macroscopic gastrointestinal haemorrhage, stomatitis, gastritis, eructation Uncommon Colitis, gastroduodenal ulcer, oesophagitis Rare Gastrointestinal perforation Very rare Gastrointestinal haemorrhage, ulceration or perforation may sometimes be severe and potentially fatal, especially in elderly (see section Special Warnings and Precautions). Hepato-biliary disorders Liver function disorder (e.g. raised transaminases or bilirubin) Uncommon Hepatitis Very rare Skin and subcutaneous tissue disorders Angioedema, pruritus, rash Uncommon Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria Rare Dermatitis bullous, erythema multiforme Very rare Photosensitivity reaction Not known Renal and urinary disorders Sodium and water retention, hyperkalaemia (see section Special Warnings and Precautions and section Drug Interactions.), renal function test abnormal (increased serum creatinine and/or serum urea) Uncommon Acute renal failure in particular in patients with risk factors (see section Special Warnings and Precautions.) Very rare General disorders and administration site conditions Oedema including oedema of the lower limbs Uncommon
c) Information Characterising Individual Serious and/or Frequently Occurring Adverse Reactions Very rare cases of agranulocytosis have been reported in patients treated with meloxicam and other potentially myelotoxic drugs (see section Drug Interactions). d) Adverse reactions which have not been observed yet in relation to the product, but which are generally accepted as being attributable to other compounds in the doss Organic renal injury probably resulting in acute renal failure: very rare cases of interstitial nephritis, acute tubular necrosis, nephrotic syndrome, and papillary necrosis have been reported (see section Special Warnings and Precautions).
Dosage and Administration:  Oral use The total daily amount should be taken as a single dose, with water or another liquid, during a meal. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section Special Warnings and Precautions). The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis. - Exacerbations of osteoarthrosis: 7.5 mg/day. (one 7.5 mg tablet) If necessary, in the absence of improvement, the dose may be increased to 15 mg/day. - Rheumatoid arthritis, ankylosing spondylitis: 15 mg/day (one 15 mg tablet). (See also section 'Special populations') According to the therapeutic response, the dose may be reduced to 7.5 mg/day DO NOT EXCEEDTHE DOSE OF 15 MG/DAY.
Special populations  Elderly patients and patients with increased risks for adverse reaction (see section Pharmacokinetic Properties): The recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day. Patients with increased risks for adverse reactions should start treatment with 7.5 mg per day (see section Special Warnings and Precautions). Renal impairment (see section Pharmacokinetic Properties): In dialysis patients with severe renal failure, the dose should not exceed 7.5 mg per day. No dose reduction is required in patients with mild to moderate renal impairment (i.e. patients with a creatimne clearance of greater than 25 ml/mini. (For patients with non-dialysed severe renal failure, see section Contraindications) Hepatic impairment (see section Pharmacokinetic Properties): No dose reduction is required in patients with mild to moderate hepatic impairment (For patients with severely impaired liver function, see section Contraindications). Children and adolescents: MOBIC tablets is contraindicated in children and adolescents aged under 16 years (see section Contraindications). This medicinal product exists in other dosages, which may be more appropriate.
Overdosage  Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Severe poisoning may result in hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse and cardiac arrest. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs and may occur following an overdose. Patients should be managed with symptomatic and supportive care following an NSAID overdose. Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial.
Availability Tablets 7.5 mg and 15 mg
Date of Package Insert: April 2009 (SPC)
Storage instructions:  Store in a safe place below 30° C. Store in a safe place out of the reach of children! Store in the original package, in order to protect from moisture.
Manufactured by Boehringer Ingelheim Pharma GmbH & Co. KG for Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
This is a medicament - Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you. - Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament - The doctors and the pharmacist are experts in medicine, its benefits and risks. - Do not by yourself interrupt the period of treatment prescribed for you. - Do not repeat the same prescription without consulting your doctor.
Keep medicament out of reach of children!
Council of Arab Health Ministers - Union of Arab Pharmacists*
A
P-7
A
L
71433-03 ••• 1157/NAF/3